Endocrinology
From the Journals
Cortisol levels on COVID-19 admission may be a marker of severity
Those with COVID-19 do appear to mount a stress response to the infection, and cortisol levels on admission to hospital can help determine the...
Conference Coverage
T2D plus heart failure packs a deadly punch
Medical records from 150,000 Danish patients with type 2 diabetes showed heart failure comorbidity was the deadliest combination.
From the Journals
Where does dexamethasone fit in with diabetic ketoacidosis in COVID-19?
Author of new article discussing considerations around diabetic ketoacidosis in the setting of COVID-19 also speaks to the findings this week that...
Conference Coverage
Increased hypothyroidism risk seen in young men with HS
This finding was surprising, according to a researcher.
Conference Coverage
DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients
Latest News
Daily Recap: FDA revokes emergency use of hydroxychloroquine; Hardest hit specialties ranked in financial report
Volunteer “street medics” -- nursing students, veterinarians, doctors, trauma surgeons, security guards, ski patrollers, nurses, wilderness EMTs,...
From the Journals
Cognitive-behavioral therapy a standout for better immune function
"More research needs to be done to determine how the present findings might be translated into treatment options or public policy," said Dr....
Conference Coverage
For COVID-19 plus diabetes, glycemic control tops treatment list
Tight glucose control led to better results in patients with diabetes and COVID-19.
Conference Coverage
Diabetes hospitalizations halved with FreeStyle Libre glucose monitor
Hospitalizations for diabetic ketoacidosis, diabetes-related emergencies, and all-cause hospitalizations were reduced following initiation of...
Conference Coverage
Half of young adults with diabetes have diastolic dysfunction
Measures of diastolic dysfunction, a heart failure precursor, from tissue Doppler echo showed high prevalence rates in young patients with...
Conference Coverage
EMPA-REG OUTCOME: Empagliflozin cut insulin need in type 2 diabetes
Post-hoc analysis from EMPA-REG OUTCOME showed that type 2 diabetes patients who received empagliflozin had less need for insulin than controls....